ARRAY BIOPHARMA BEGINS TRIAL OF MEK INHIBITOR

A A

Array BioPharma has announced the initiation of a Phase I clinical trial for its proprietary small molecule, ARRY-438162, a novel MEK inhibitor for the treatment of inflammatory disease.

ARRY-438162 will be evaluated in dose escalation studies in normal, healthy volunteers. ARRY-438162 was potent, selective, well-tolerated and efficacious in preclinical models of human inflammatory diseases.

MEK is a protein kinase that regulates both the biosynthesis of and response to a number of growth factors that drive uncontrolled inflammation associated with many human diseases.